Monthly Archives: March 2013

Healthcare Systems in Europe "Failing Patients"

By Reflector, Brussels correspondent. Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault in Dublin, Ireland, last week, at a conference organized under the auspices of the Irish Presidency of the European Union and featuring a galaxy of Irish and European stars […]
Posted in Europe, Guest Blog, healthcare, Op-Ed | Tagged , , , , , , | 1 Comment

Social Media Guidelines: In Pursuit of a Policy

You don’t have a social media policy yet? Oh, you do, you just didn’t tell your staff? By Peter Houston. A few weeks back I wrote on this blog about the need for CEOs to get social. I’m realistic, I know that the majority of CEOs still don’t engage directly in social media. Mostly it’s […]
Posted in Global, Guest Blog, Op-Ed, social media | Tagged , | 2 Comments

The FTC's Beef with Pay For Delay: What's the Fuss?

Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive on the grounds that these settlements amount to a restraint of trade under the commerce clause of the […]
Posted in IP, Legal, Market Access, Regulatory | Tagged , , , , | 1 Comment

FTC v. Actavis: The Wrong End of the Telescope

by Traci Medford-Rosow and Peter C. Richardson On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case. The court’s grant of certiorari marked the latest chapter in a decade-long effort by the FTC to have the court rule on the festering issue of whether pay-for-delay provisions […]
Posted in IP, Legal, Market Access, Op-Ed, Regulatory, Strategy | Tagged , | 1 Comment

AstraZeneca's R&D Trimdown, Points to Shift in The Way Big Pharma Invents

AstraZeneca’s decision to cut 5,050 jobs by 2016 and cease R&D operations at its Alderley Park, UK facility has many wondering where CEO Pascal Soriot plans to take the company. The opening of a new $500 million facility in Cambridge is at once a consolation prize for the UK government’s efforts to placate a skittish […]
Posted in Biotech, Europe, R&D, Strategy | Tagged , , | Leave a comment
  • Categories

  • Meta